Chemotherapy-induced Peripheral NeuropathyNCT07177820
VGAIT for Chemotherapy-induced Peripheral Neuropathy
A study testing Video-Guided Acupuncture Imagery Treatment (VGAIT) in people with Chemotherapy-induced Peripheral Neuropathy, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
Perform a feasibility study on imagined acupuncture treatment of Chemotherapy-induced peripheral neuropathy (CIPN) Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Chemotherapy-induced Peripheral Neuropathy
- What is being tested?
- Video-Guided Acupuncture Imagery Treatment (VGAIT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jan 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- at least 18 years of age
- have histologically confirmed stage I-III breast cancer,
- have completed adjuvant taxane-based chemotherapy (alone or in combination), ,
- have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Who cannot join
- concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),
- having metastatic or recurrent disease,
- history of preexisting peripheral neuropathy prior to chemotherapy,
- uncontrolled seizure disorder,
- unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Massachusetts General Hospital
Charlestown, Massachusetts, 02129
Sierra Hodges, B.S., 617-726-5004, sahodges@mgb.org
About this study
Official title: Video-Guided Acupuncture Imagery Treatment in Chemotherapy-induced Peripheral Neuropathy
Perform a feasibility study on imagined acupuncture treatment of Chemotherapy-induced peripheral neuropathy (CIPN)
Read the detailed description
We will perform a pilot study to assess the feasibility of Video-Guided Acupuncture Imagery Treatment (VGAIT) on CIPN symptoms in patients with stage I-III breast cancer with persistent CIPN after adjuvant chemotherapy. Participants will receive 16 sessions of VGAIT over 8 weeks remotely through the zoom. Study measures will be collected at the time of study enrollment, week 4, and week 8. The primary endpoints of the study will be 1) retention to treatment; 2) satisfaction for the intervention and 3) completion of study assessments.
- Being tested
- Video-Guided Acupuncture Imagery Treatment (VGAIT)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Video-Guided Acupuncture Imagery Treatment (VGAIT)Other
Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them
| Study group | Role | What they receive |
|---|---|---|
| VGAIT | Experimental | Not described Receives: Other: Video-Guided Acupuncture Imagery Treatment (VGAIT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility related outcomes
Completion, satisfaction
Measured: 8 week
Secondary outcomes (6)
Patient Neurotoxicity Questionnaire (PNQ)
A tool designed to assess neurotoxic effects in patients who have undergone treatments such as chemotherapy
Measured: baseline, 8 week
Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX)
a widely used, validated instrument that assesses the impact of neuropathy on health-related quality of life
Measured: baseline, 8 week
Brief Pain Inventory-short form (BPI-SF)
An instrument used to evaluate the severity of pain, including neuropathic pain, and the impact on the patient's daily functioning.
Measured: baseline, 8 week
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (QLQ-C30) instrument
an instrument developed to assess the quality of life in cancer patients
Measured: baseline, 8 week
MGH Acupuncture Sensation Scale (MASS)
scale includes 12 descriptors of sensations frequently described during acupuncture treatment
Measured: after each intervention
Pain Catastrophizing Scale (PCS)
a 13-item self-report scale which measures pain-related rumination, magnification, and helplessness
Measured: baseline, 8 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start6 Jan 2026
- Primary completion1 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chemotherapy-induced Peripheral NeuropathyStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Video-Guided Acupuncture Imagery Treatment
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jian Kong, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177820
- Sponsor's protocol ID
- 25-307
- Status last verified
- Jul 2026
- First submitted
- 21 Jul 2025
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Video-Guided Acupuncture Imagery Treatment in Chemotherapy-induced Peripheral Neuropathy
- ClinicalTrials.gov ID
- NCT07177820
- Acronym / sponsor ID
- 25-307
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Study start
- 6 Jan 2026 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Perform a feasibility study on imagined acupuncture treatment of Chemotherapy-induced peripheral neuropathy (CIPN)
Detailed description
We will perform a pilot study to assess the feasibility of Video-Guided Acupuncture Imagery Treatment (VGAIT) on CIPN symptoms in patients with stage I-III breast cancer with persistent CIPN after adjuvant chemotherapy. Participants will receive 16 sessions of VGAIT over 8 weeks remotely through the zoom. Study measures will be collected at the time of study enrollment, week 4, and week 8. The primary endpoints of the study will be 1) retention to treatment; 2) satisfaction for the intervention and 3) completion of study assessments.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Video-Guided Acupuncture Imagery Treatment
| Arm | Type | Receives |
|---|---|---|
| VGAIT | Experimental | Other: Video-Guided Acupuncture Imagery Treatment (VGAIT) |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- at least 18 years of age
- have histologically confirmed stage I-III breast cancer,
- have completed adjuvant taxane-based chemotherapy (alone or in combination), ,
- have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Key exclusion criteria (5 listed)
- concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),
- having metastatic or recurrent disease,
- history of preexisting peripheral neuropathy prior to chemotherapy,
- uncontrolled seizure disorder,
- unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Video-Guided Acupuncture Imagery Treatment (VGAIT)Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them | Other | VGAIT |
Primary outcome
Feasibility related outcomes
Time frame: 8 week
Completion, satisfaction
6 secondary outcomes
Patient Neurotoxicity Questionnaire (PNQ)
Time frame: baseline, 8 week
Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX)
Time frame: baseline, 8 week
Brief Pain Inventory-short form (BPI-SF)
Time frame: baseline, 8 week
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (QLQ-C30) instrument
Time frame: baseline, 8 week
MGH Acupuncture Sensation Scale (MASS)
Time frame: after each intervention
Pain Catastrophizing Scale (PCS)
Time frame: baseline, 8 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
Related trials for Chemotherapy-induced Peripheral Neuropathy
RecruitingEarly Phase 1
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC)
Not yet recruitingPhase 2
Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
Breast Cancer, Peripheral Neuropathy Due to Chemotherapy
RecruitingPhase 2
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Not yet recruiting
AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Active, not recruitingPhase 2
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Video-Guided Acupuncture Imagery Treatment (VGAIT) in people with Chemotherapy-induced Peripheral Neuropathy, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sierra Hodges (6177265004, sahodges@mgb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility related outcomes (time frame: 8 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.